Business Wire

CA-SENTRY

4.5.2022 15:02:13 CEST | Business Wire | Press release

Share
Sentry Raises $90 Million in Series E Funding to Expand and Drive Adoption of Developer-first Application Monitoring

Sentry , the market leader in developer-first application monitoring, today announced it has raised $90 million for its Series E, bringing the company’s total funding to $217 million and valuing the company at more than $3 billion. This round was co-led by BOND and Accel , with participation from existing investor New Enterprise Associates (NEA) and new investor K5 Global . The new capital will help fuel the company’s long-term growth for product development, hiring, and global expansion in Europe.

Sentry is reshaping application performance monitoring (APM) by directly addressing the developer experience gap. With the proliferation of applications, languages, and frameworks, Sentry empowers any developer or development team to solve issues in production code by using one tool to monitor for errors, performance, and health across mobile, desktop, and IoT, and across any industry or vertical.

In the past year, the company saw rapid growth driven by customer adoption of Error and Performance Monitoring, with net expansion of annual recurring revenue (ARR) increasing by 130%+ year over year. Sentry now processes 790+ billion events per month, with mobile events increasing by more than 100% year over year.

“Our singular focus on developers, combined with the depth of our platform across 100+ languages, allows us to uniquely solve developer problems for every customer and software environment,” said Milin Desai, CEO at Sentry. “Revenue has more than tripled in just over two years, and our team will continue to be laser-focused on providing engineering organizations with the ability to ship better code faster.”

"Our customers expect constant improvements to the product experience along with new feature updates, and without any disruptions to their current workflows,” said Kah Seng Tay, GM and Head of Cloud and Developer Infrastructure at Airtable . “With Sentry providing accurate and diagnosable alerts, we’re able to better triage incidents during deployment and decentralize our release process. This all results in our engineering teams being able to ship code more efficiently and more frequently, while still keeping the quality of our service high."

“We ship a tremendous amount of code — eight deployments at the top of every hour — to launch new features. Combined with a highly distributed architecture, it was getting more and more complex for our teams to identify and fix errors and performance issues,” said Eviathar Moussaffi, Group Lead of Engineering at monday.com . “Providing the most optimal user experience to our customers is critical to the success of our business, and Sentry allows us to eliminate unnecessary noise and reduces the time to resolution, so our developers can be most effective. The demands on our business are only going to increase, and Sentry provides a way for our team to have a holistic view of the health of our applications.”

“The rate at which businesses are moving towards a digital-first mindset is unprecedented,” said Jay Simons , General Partner at BOND. “In order to sustain applications, programs, and mobile, the proper infrastructure needs to be in place to manage and monitor the health of every customer solution. For many businesses, an error in code or a performance issue in the final touchpoint with an end-user can mean the loss of a sale or customer.”

“The rate of software development is going to exponentially increase, and developers are seeking ways to quickly solve any issues that will affect the end-user experience,” said Dan Levine , Partner at Accel, a firm that has also invested in companies like Atlassian, CrowdStrike, Dropbox, PagerDuty, Qualtrics, and Slack. “With Sentry, companies can not only pinpoint the exact issue but also proactively monitor their application health. As we continue to see the move towards a digital-first world, Sentry is well-positioned to help companies, from small businesses to enterprises, ensure that they’re keeping up with customer expectations.”

To support growing demand, Sentry’s team has grown nearly 75% worldwide since this time last year, with plans to continue hiring for all offices, including a new hub opening in Europe. With this round of funding, Sentry will accelerate its go-to-market motion and teams, as the company expands on its product-led growth model and servicing its global customer base.

Learn more about Sentry’s plans for innovation and growth on the company blog .

About Sentry

For software teams, Sentry is essential for monitoring code health. From Error tracking to Performance Monitoring, developers can see clearer, solve quicker, and learn continuously about their applications — from frontend to backend. Loved by more than 3.5 million developers and 85,000 organizations worldwide, Sentry provides code-level observability to many of the world’s best-known companies like Disney, Peloton, Cloudflare, Eventbrite, Slack, Supercell, and Rockstar Games. Learn more at sentry.io or follow Sentry on GitHub , Twitter , Dribbble or LinkedIn .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Philip Morris International and Maestro Andrea Bocelli Present “Believe. Further”29.6.2026 12:00:00 CEST | Press release

A new platform for dialogue on progress, reflecting a mutual commitment to advancing positive change Philip Morris International (PMI) (NYSE: PM) and Maestro Andrea Bocelli today presented “Believe. Further”, a multi-year platform designed to engage audiences in a broader conversation on progress and positive change. The launch took place at the Torre dell’Arsenale in Venice, where heritage and forward movement meet, a fitting setting for two voices on a similar path. What do you do when the world has already decided what you are? “Believe. Further” begins from that question. It is built around a shared belief in progress and a shared conviction in transformation. At a time when science and technology allow better choices, it brings together two voices that, independently and in parallel, are undergoing a change in motion, and invites the beginning of a different conversation with society at large. Maestro Bocelli’s journey has been defined by belief. From the beginnings of his career

Doubtless Pet Care Launches to Provide Peace of Mind to Pet Parents and Help Their Pets Live Happier, Healthier Lives29.6.2026 10:15:00 CEST | Press release

Doubtless combines industry-leading pet insurance with innovative care solutions, protecting more than 6 million pets across 10 global markets Doubtless launches today with the goal of helping more pet parents across the world access quality care for the pets they love. The company brings together a leading global portfolio of pet insurance brands with a growing range of connected solutions designed to support pet parents at every stage of their pet’s life. With over 4,000 employees, Doubtless insures 6 million pets across 10 markets in North America, Europe and the United Kingdom. “Uncertainty about the financial commitments associated with having a pet should never keep families from experiencing the joy of a life with pets,” said Dirk Beeckman, CEO of Doubtless. “By harnessing the power of our international footprint, we are building on our leadership in pet insurance to create a global suite of solutions for pet parents, veterinarians and industry partners that makes pet care easie

Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release

Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie

IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release

IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi

Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release

Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye